Seeking informed consent to Phase I cancer clinical trials: identifying oncologists' communication strategies. Academic Article uri icon

Overview

abstract

  • PURPOSE: Phase I clinical trials are the gateway to effective new cancer treatments. Many physicians have difficulty when discussing Phase I clinical trials. Research demonstrates evidence of suboptimal communication. Little is known about communication strategies used by oncologists when recruiting patients for Phase I trials. We analyzed audio recorded Phase I consultations to identify oncologists' communication strategies. PATIENTS AND METHODS: Subjects were consecutive cancer patients from six medical oncologists attending one of three outpatient clinics at a major Cancer Center in the United States. Sixteen patients signed informed consent for audio recording of their consultations in which a Phase I study was discussed. These were transcribed in full and analyzed to identify communication strategies. RESULTS: Six communication themes emerged from the analysis: (1) orienting, (2) educating patients, (3) describing uncertainty and prognosis, (4) persuading, (5) decision making, and (6) making a treatment recommendation. As expected, although there was some common ground between communication in Phase I and the Phase II and III settings, there were distinct differences. CONCLUSIONS: Oncologists used persuasive communication, made explicit recommendations, or implicitly expressed a treatment preference and were choice limiting. This highlights the complexity of discussing Phase I trials and the need to develop strategies to aid oncologists and patients in these difficult conversations. Patient centered communication that values patient preferences while preserving the oncologist's agenda can be a helpful approach to these discussions.

publication date

  • April 7, 2010

Research

keywords

  • Clinical Trials, Phase I as Topic
  • Communication
  • Informed Consent
  • Physician-Patient Relations

Identity

Scopus Document Identifier

  • 79952999925

Digital Object Identifier (DOI)

  • 10.1002/pon.1748

PubMed ID

  • 20878842

Additional Document Info

volume

  • 20

issue

  • 4